Skip to main navigation Skip to search Skip to main content

The metabolic fate of the anti-Parkinsonian drug budipine in rats

  • O. Caputo
  • , G. Grosa
  • , M. Ceruti
  • , F. Rocco
  • , G. Biglino

Research output: Contribution to journalArticlepeer-review

Abstract

The metabolic fate of the anti-Parkinsonian drug budipine was studied in rats after oral administration. The presence of an aromatic hydroxylation product, metabolite Mi, and its O-sulphate conjugate was confirmed. Three new minor metabolites, budipine N-oxide, metabolite M1 N-oxide and a secondary metabolite derived from M1 via hydroxylation of a methyl of the tert-butyl group, were isolated and identified in rat urine. The presence of a metabolite M1-glucuronic acid conjugate, was also established through different enzymatic treatments of the rat urine.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume16
Issue number2
DOIs
Publication statusPublished - Apr 1991
Externally publishedYes

Keywords

  • 1-tert-butyl-4,4-diphenylpiperidine
  • BY-701
  • Budipine
  • anti-Parkinsonian
  • metabolism

Fingerprint

Dive into the research topics of 'The metabolic fate of the anti-Parkinsonian drug budipine in rats'. Together they form a unique fingerprint.

Cite this